Shares of Biogen Inc. BIIB shed 2.23% to $129.79 Friday, on what proved to be an all-around mixed trading session for the ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Shares of Biogen Inc. BIIB rose 4.09% to $132.75 Thursday, on what proved to be an all-around positive trading session for ...

Major indices traded higher early on Thursday as market participants digested news that a federal court had struck down ...

Biogen and City Therapeutics have announced a partnership worth over $1bn to develop new RNAi therapies. The collaboration ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Nearly two years in with Zurzuvae, Biogen tackles an ‘all of the above market’ to find patients and battle stigma in ...

Biogen Inc. (NASDAQ:BIIB)’s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous ...

A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments.

Biogen (NasdaqGS:BIIB) recently announced a collaboration with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases, contributing to a 6% share price increase over the ...

Biogen ( NASDAQ: BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ( (RNAi)) therapies ...

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...